89bio

77 articles about 89bio

• 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

  4/17/2024

  89bio, Inc. announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024.

• 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024

  4/5/2024

  89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new employees on April 3, 2024.

• 

  FDA Approves Madrigal’s Rezdiffra as First MASH Therapy

  3/15/2024

  Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) is the first-ever approved therapy for metabolic dysfunction-associated steatohepatitis—a decision experts say could signal a sea change in treatment of the disease.

• 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

  3/12/2024

  89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).

• 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  3/8/2024

  89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 10,800 shares of the Company’s common stock to a new employee on March 6, 2024.

• 89bio to Participate in the Leerink Partners Global Biopharma Conference

  3/5/2024

  89bio, Inc. announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 1:40 PM EST and participate in one-on-one investor meetings.

• 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

  2/29/2024

  89bio, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided corporate updates.

• 89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

  2/6/2024

  89bio, Inc. announced that the Company’s Management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST and participate in one-on-one investor meetings.

• 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 05, 2024

  2/5/2024

  89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 28,400 shares of the Company’s common stock to two new employees on the later of February 2, 2024 and the employee’s commencement of employment with the Company.

• 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2023

  12/19/2023

  89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,000 shares of the Company’s common stock to two new employees on the later of December 13, 2023 and the employee’s commencement of employment with the Company.

• 89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  12/12/2023

  89bio, Inc. today announced that it closed its previously announced upsized underwritten public offering of 17,567,567 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 2,432,432 shares.

• 89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

  12/7/2023

  89bio, Inc. today announced the pricing of its previously announced upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25.

• 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - December 06, 2023

  12/6/2023

  89bio, Inc. announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

• 89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

  12/4/2023

  89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced a successful end-of-Phase 2 Meeting with the U.S. Food & Drug Administration (FDA), supporting the advancement of pegozafermin into Phase 3 in NASH.

• 89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

  11/27/2023

  89bio, Inc. today announced positive topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).

• 89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

  11/12/2023

  89bio, Inc. announced additional data from a post-hoc analysis of the ENLIVEN Phase 2b trial evaluating treatment with pegozafermin in a subgroup of patients with F4 NASH.

• 89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

  11/8/2023

  89bio, Inc. reported its financial results for the third quarter ended September 30, 2023.

• 89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

  10/17/2023

  89bio, Inc. announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference being held on Tuesday, October 24, 2023.

• 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2023

  10/3/2023

  89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 116,000 shares of the Company’s common stock to four new employees on the later of September 28, 2023 and the employee’s commencement of employment with the Company.

• 89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

  9/21/2023

  89bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pegozafermin in patients with nonalcoholic steatohepatitis (NASH).